Skip Navigation

JNCI Monographs 2007 2007(37):1-4; doi:10.1093/jncimonographs/lgm001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Minasian, L.
Right arrow Articles by O'Mara, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Minasian, L.
Right arrow Articles by O'Mara, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2007.

Introduction

Lori Minasian, Ann O'Mara

Affiliation of authors: Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD

Correspondence to: Lori Minasian, MD, National Cancer Institute, 6130 Executive Blvd, MSC-7340, Bethesda, MD 20892-7340 (e-mail: minasilo@mail.nih.gov).

The first 150 words of the full text of this article appear below.


   INTRODUCTION
 
Over the past 30 years, National Cancer Institute (NCI) has supported quality of life (QOL) assessments in conjunction with its clinical trials and convened periodic workshops to review the progress of its inclusion as an endpoint (1,2). In 2003, the NCI staff initiated a systematic review of health-related quality of life (HRQL) assessments in the symptom management clinical trials conducted through the Community Clinical Oncology Program (CCOP). The review evaluated whether assessing QOL contributed additional value to the results of the trials beyond the effect of the intervention on the designated symptom (3). In practice, a clinician would treat a patient's symptoms even if the successful resolution of those symptoms did not result in an improvement in the patient's overall QOL (4).

The CCOP program is an NCI-funded clinical trials network and the primary mechanism to support NCI-sponsored symptom management clinical trials. . . . [Full Text of this Article]


   Assessing Quality of Life (QOL) in Cancer Symptom Management Trials Workshop
 
Participants List


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?